US Edition
Novo Weight-Loss Drug May Preserve Lean Body Mass Better than Lilly’s, Study Finds - Regional Media News
4 Articles
4 Articles
Semalgutide, the active principle of the drugs Ozempic and Wegovy, of the pharmaceutical Novo Nordisk, can better preserve muscle mass during weight loss than the Tirzepatide, of the Mounjaro, produced by Eli Lilly. It is what indicates a new study that analyzed data of almost 700,000 people. Both substances are used in the treatment of type 2 diabetes and obesity. The work, which was made available as a pre-print, that is, it has not yet been r…
Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests
While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to a new study awaiting peer review. The analysis, shared as ...
Novo weight-loss drug may preserve lean body mass better than Lilly’s, study finds - Regional Media News
By Nancy Lapid April 16 (Reuters) - Eli Lilly's GLP-1 drug tirzepatide yields greater weight loss on average than Novo Nordisk's semaglutide, but at a greater expense to muscles and connective tissues, according to a study published this week ahead of peer review. Tirzepatide, sold as Zepbound and Mounjaro, and semaglutide, under the brand names Wegovy and Ozempic, have become wildly popular for weight loss and have demonstrated other health ben…
A recent study, which has not yet been peer-reviewed, found that Eli Lilly's tirzepatide drug resulted in greater weight loss on average than Novo Nordisk's semaglutide. However, this treatment was also associated with greater loss of muscle and fat-free mass.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
